SCHEMBL19614370

SCHEMBL19614370

O=C1NCC2(CCCC2)n2c1cc(=O)c1cncnc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 20/20 0.43
▸ CDK4 P11802 15/20 0.43
▸ CCND1 P24385 15/20 0.43
▸ CCNE1 P24864 13/20 0.43
▸ CCND3 P30281 5/20 0.43
▸ CDK6 Q00534 5/20 0.43
▸ CCNT1 O60563 4/20 0.43
▸ CDK9 P50750 4/20 0.43
▸ CCNA2 P20248 2/20 0.43
▸ CDK1 P06493 1/20 0.40
▸ CDK7 P50613 1/20 0.40
▸ CDK3 Q00526 1/20 0.40
▸ CDK5R1 Q15078 1/20 0.40
▸ TTK P33981 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ CCNH P51946 1/20 0.39
▸ NEK10 Q6ZWH5 1/20 0.39
▸ ULK2 Q8IYT8 1/20 0.39
▸ NUAK2 Q9H093 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30364404 0.84 CDK2 (0.53) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL21014427 0.72 CDK2 (0.56) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL16081518 0.72 CDK2 (0.61) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL4549860 0.72 CDK2 (0.56) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL31252716 0.71 CDK2 (0.57) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL15249224 0.71 CDK2 (0.57) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL22570004 0.71 CDK2 (0.63) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL21388312 0.70 CDK2 (0.54) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL22570112 0.69 CDK2 (0.66) CDK2CDK4CCND1CCNE1CCND3
SCHEMBL25949551 0.69 CDK2 (0.53) CDK2CDK4CCND1CCNE1CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10376519-B2 Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation G1 THERAPEUTICS, INC. (US) 2019-08-13 — — US disclosed
US-20170333440-A1 TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2017-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333440-A1 TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION CDK4, CDK6, CDKL4 CDK2 16/4885CDK4 1/4885CCND1 53/4885
US-10376519-B2 Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation CDK4, CDK6, CDKL4 CDK2 16/4885CDK4 1/4885CCND1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback